Cibus Global Net Income Over Time
| CBUS Stock | 2.28 0.20 9.62% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Cibus Global Performance and Cibus Global Correlation. Is there potential for Biotechnology market expansion? Will Cibus introduce new products? Factors like these will boost the valuation of Cibus Global. Projected growth potential of Cibus fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Cibus Global listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.72) | Revenue Per Share | Quarterly Revenue Growth (0.63) | Return On Assets | Return On Equity |
Cibus Global LLC's market price often diverges from its book value, the accounting figure shown on Cibus's balance sheet. Smart investors calculate Cibus Global's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since Cibus Global's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Cibus Global's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cibus Global should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Cibus Global's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare Cibus Global LLC and related stocks such as Biomea Fusion, Vaxart Inc, and Pmv Pharmaceuticals Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BMEA | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (5.3 M) | (41.2 M) | (80 M) | (117.3 M) | (138.4 M) | (124.6 M) | (118.4 M) |
| VXRT | 1000 K | (4.5 M) | (8.7 M) | (8.9 M) | (11 M) | (19.1 M) | (25.4 M) | (12.5 M) | (18 M) | (18.6 M) | (32.2 M) | (70.5 M) | (107.8 M) | (82.5 M) | (66.9 M) | (60.3 M) | (57.2 M) |
| PMVP | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (17.5 M) | (25.4 M) | (34.4 M) | (57.8 M) | (73.3 M) | (69 M) | (58.7 M) | (52.8 M) | (55.5 M) |
| IMUX | (5.9 M) | (5.9 M) | (6.7 M) | (32.7 M) | (47.7 M) | (52 M) | (41 M) | (52.1 M) | (41.5 M) | (34.8 M) | (44 M) | (92.8 M) | (120.4 M) | (93.6 M) | (100.5 M) | (90.5 M) | (85.9 M) |
| ACRV | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (16.2 M) | (29.7 M) | (60.4 M) | (80.6 M) | (72.5 M) | (68.9 M) |
| RPTX | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (14.3 M) | (27.2 M) | (53.4 M) | (106.9 M) | (29 M) | (93.8 M) | (84.7 M) | (76.2 M) | (80 M) |
| RLMD | (12.1 K) | (12.1 K) | (12.1 K) | (45 K) | (20.8 M) | (20.8 M) | (3 M) | (6.3 M) | (9 M) | (15 M) | (59.5 M) | (125.8 M) | (157 M) | (98.8 M) | (80 M) | (72 M) | (75.6 M) |
| UNCY | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (2.3 M) | (2.5 M) | (10.6 M) | (18.1 M) | (30.5 M) | (36.7 M) | (33.1 M) | (31.4 M) |
| MNOV | (1.8 M) | (17.7 M) | (11 M) | (4 M) | (9.2 M) | (8.8 M) | (10.9 M) | (11.2 M) | (14.7 M) | (12.9 M) | (13.9 M) | (10.1 M) | (14.1 M) | (8.6 M) | (11 M) | (12.7 M) | (13.3 M) |
| CAMP | (5.7 M) | 5.2 M | 44.6 M | 11.8 M | 16.5 M | 16.9 M | (7.2 M) | 16.6 M | 18.4 M | (78.8 M) | (21.2 M) | (31.1 M) | (44.2 M) | (49.3 M) | (51.8 M) | (46.6 M) | (44.3 M) |
Cibus Global LLC and related stocks such as Biomea Fusion, Vaxart Inc, and Pmv Pharmaceuticals Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Cibus Global LLC financial statement analysis. It represents the amount of money remaining after all of Cibus Global LLC operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Cibus Global LLC | CBUS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 6455 Nancy Ridge |
| Exchange | NASDAQ Exchange |
null 2.28
Additional Tools for Cibus Stock Analysis
When running Cibus Global's price analysis, check to measure Cibus Global's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cibus Global is operating at the current time. Most of Cibus Global's value examination focuses on studying past and present price action to predict the probability of Cibus Global's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cibus Global's price. Additionally, you may evaluate how the addition of Cibus Global to your portfolios can decrease your overall portfolio volatility.